| 1 |
Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium[J]. J Antibiot (Tokyo), 1976, 29(12):1346-1348.
|
| 2 |
Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase[J]. Science, 2001, 292(5519):1160-1164.
|
| 3 |
Goldstein JL, Brown MS. Regulation of the mevalonate pathway[J]. Nature, 1990, 343(6257):425-430.
|
| 4 |
Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)[J]. Lancet, 1994, 344(8934):1383-1389.
|
| 5 |
Shepherd J, Cobbe S M, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia[J]. N Engl J Med, 1995, 333(20):1301-1307.
|
| 6 |
Owens AR, Mackman N. The antithrombotic effects of statins[J]. Annu Rev Med, 2014, 65(1):433-445.
|
| 7 |
Van Aelst L, D′Souza-Schorey C. Rho GTPases and signaling networks[J]. Genes Dev, 1997, 11(18):2295-2322.
|
| 8 |
Yoshida M, Sawada T, Ishii H, et al. Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism[J]. Arterioscler Thromb Vasc Biol, 2001, 21(7):1165-1171.
|
| 9 |
Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo[J]. Arterioscler Thromb Vasc Biol, 2002, 22(2):300-305.
|
| 10 |
Feinberg MW, Lin Z, Fisch S, et al. An emerging role for Kruppel-like factors in vascular biology[J]. Trends Cardiovasc Med, 2004, 14(6):241-246.
|
| 11 |
刘忠忠，钟自彪，李明霞，等. Kruppel样因子2在肝肾中的保护作用[J]. 中华实验外科杂志，2015, 32(9):2324-2326.
|
| 12 |
Marrone G, Russo L, Rosado E, et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins[J]. J Hepatol, 2013, 58(1):98-103.
|
| 13 |
Marrone G, Maeso-Diaz R, Garcia-Cardena G, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins[J]. Gut, 2015, 64(9):1434-1443.
|
| 14 |
Montalvo-Jave EE, Escalante-Tattersfield T, Ortega-Salgado JA, et al. Factors in the pathophysiology of the liver ischemia-reperfusion injury[J]. J Surg Res, 2008, 147(1):153-159.
|
| 15 |
Gracia-Sancho J, Villarreal GJ, Zhang Y, et al. Flow cessation triggers endothelial dysfunction during organ cold storage conditions: strategies for pharmacologic intervention[J]. Transplantation, 2010, 90(2):142-149.
|
| 16 |
Peralta C, Jimenez-Castro MB, Gracia-Sancho J. Hepatic ischemia and reperfusion injury: effects on the liver sinusoidal milieu[J]. J Hepatol, 2013, 59(5):1094-1106.
|
| 17 |
Sorensen KK, Simon-Santamaria J, Mccuskey RS, et al. Liver sinusoidal endothelial cells[J]. Compr Physiol, 2015, 5(4):1751-1774.
|
| 18 |
Monkemoller V, Schuttpelz M, Mccourt P, et al. Imaging fenestrations in liver sinusoidal endothelial cells by optical localization microscopy[J]. Phys Chem Chem Phys, 2014, 16(24):12576-12581.
|
| 19 |
Ding BS, Cao Z, Lis R, et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis[J]. Nature, 2014, 505(7481):97-102.
|
| 20 |
Senbanerjee S, Lin Z, Atkins GB, et al. KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation[J]. J Exp Med, 2004, 199(10):1305-1315.
|
| 21 |
Lin Z, Kumar A, Senbanerjee S, et al. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function[J]. Circ Res, 2005, 96(5):e48-e57.
|
| 22 |
Parmar KM, Larman HB, Dai G, et al. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2[J]. J Clin Invest, 2006, 116(1):49-58.
|
| 23 |
Fledderus JO, Boon RA, Volger OL, et al. KLF2 primes the antioxidant transcription factor Nrf2 for activation in endothelial cells[J]. Arterioscler Thromb Vasc Biol, 2008, 28(7):1339-1346.
|
| 24 |
Warabi E, Takabe W, Minami T, et al. Shear stress stabilizes NF-E2-related factor 2 and induces antioxidant genes in endothelial cells: role of reactive oxygen/nitrogen species[J]. Free Radic Biol Med, 2007, 42(2):260-269.
|
| 25 |
Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury: Present concepts[J]. J Gastroenterol Hepatol, 2011, 26(Suppl 1):173-179.
|
| 26 |
Bahde R, Spiegel HU. Hepatic ischaemia-reperfusion injury from bench to bedside[J]. Br J Surg, 2010, 97(10):1461-1475.
|
| 27 |
Teoh NC, Ito Y, Field J, et al. Diannexin, a novel annexin V homodimer, provides prolonged protection against hepatic ischemia-reperfusion injury in mice[J]. Gastroenterology, 2007, 133(2):632-646.
|
| 28 |
Sarin S, Kaman L, Dahiya D, et al. Effects of preoperative statin on liver reperfusion injury in major hepatic resection: a pilot study[J]. Updates Surg, 2016, 68(2):191-197.
|
| 29 |
Hide D, Ortega-Ribera M, Garcia-Pagan JC, et al. Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapy[J]. Sci Rep, 2016, 6:22107.
|
| 30 |
Temkin V, Karin M. From death receptor to reactive oxygen species and c-Jun N-terminal protein kinase: the receptor-interacting protein 1 odyssey[J]. Immunol Rev, 2007, 220:8-21.
|
| 31 |
Csak T, Velayudham A, Hritz I, et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice[J]. Am J Physiol Gastrointest Liver Physiol, 2011, 300(3):G433-G441.
|
| 32 |
Ajamieh H, Farrell G, Wong HJ, et al. Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation[J]. J Gastroenterol Hepatol, 2012, 27(8):1353-1361.
|
| 33 |
Gracia-Sancho J, Guixe-Muntet S, Hide D, et al. Modulation of autophagy for the treatment of liver diseases[J]. Expert Opin Investig Drugs, 2014, 23(7):965-977.
|
| 34 |
Rautou PE, Mansouri A, Lebrec D, et al. Autophagy in liver diseases[J]. J Hepatol, 2010, 53(6):1123-1134.
|
| 35 |
Guixé-Muntet S, de Mesquita FC, Vila S, et al. Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury[J]. J Hepatol, 2017, 66(1):86-94.
|
| 36 |
Tuuminen R, Nykanen AI, Saharinen P, et al. Donor simvastatin treatment prevents ischemia-reperfusion and acute kidney injury by preserving microvascular barrier function[J]. Am J Transplant, 2013, 13(8):2019-2034.
|
| 37 |
Liu Z, Zhang X, Xiao Qi, et al. Pretreatment donors after circulatory death with simvastatin alleviates liver ischemia reperfusion injury through a KLF2-dependent mechanism in rat[J]. Oxid Med Cell Longev, 2017:3861914.
|
| 38 |
Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation[J]. Liver Transpl, 2003, 9(7):651-663.
|
| 39 |
Gracia-Sancho J, Garcia-Caldero H, Hide D, et al. Simvastatin maintains function and viability of steatotic rat livers procured for transplantation[J]. J Hepatol, 2013, 58(6):1140-1146.
|
| 40 |
Trocha M, Merwid-Lad A, Chlebda E, et al. Effect of simvastatin treatment on rat livers subjected to ischemia/reperfusion[J]. Pharmacol Rep, 2010, 62(4):757-762.
|
| 41 |
Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis[J]. N Engl J Med, 2002, 346(7):539-540.
|
| 42 |
Kraft R, Kahn A, Medina-Franco JL, et al. A cell-based fascin bioassay identifies compounds with potential anti-metastasis or cognition-enhancing functions[J]. Dis Model Mech, 2013, 6(1):217-235.
|
| 43 |
Chen GL, Hsiao FY, Dong YH, et al. Statins and the risk of liver injury: a population-based case-control study[J]. Pharmacoepidemiol Drug Saf, 2014, 23(7):719-725.
|